Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty

Circulation

Volumn 94, Issue 11, 1996, Pages 2890-2900

  Lucas, Alexandra ^a,b   Liu, Li Ying ^a   Macen, Joanne ^a   Nash, Piers ^a   Dai, Erbin ^a   Stewart, Michael ^a   Graham, Kathryn ^a   Etches, Wai ^a   Boshkov, Lynn ^a   Nation, Patric N ^a   Humen, Dennis ^a   Hobman, Marita Lundstrom ^a   McFadden, Grant ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

angioplasty; immune system; plaque; serpin

Indexed keywords

SERINE PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME INHIBITION; FIBRINOLYSIS; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; MONONUCLEAR CELL; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RABBIT;

EID: 10544228520     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.11.2890     Document Type: Article

References (42)

1. Swartz RS, Holmes DR. Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293.
2. Ellis SG, Muller DWM. Arterial injury and the enigma of coronary restenosis. J Am Coll Cardiol. 1992;19:275-277.
3. Ross R. Atherosclerosis: a defense mechanism gone awry. Am J Pathol. 1993;143:987-1002.
4. Dzau VJ, Gibbons GH, Cooke JP, Omoigui N. Vascular biology and medicine in the 1990s: scope, concepts, potentials, and perspectives. Circulation. 1993;87:705-719.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:310-318.
6. Tanaka H, Sukhova GK, Swanson, SJ, Slinton SK, Ganz P, Cybulsky MI, Libby P. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation. 1993;88:1788-1803.
7. Altieri DC. Proteases and protease receptors in modulation of leukocyte effector functions. J Leukoc Biol. 1995;58:120-127.
8. Carmeliet P. Insights via t-PA and u-PA transgenic mice. Restenosis Summit VII. 1995:7;250-253.
9. Carmeliet P, Schoojans L, Kieckans L, Ream B, Degan J, Bronson R, DeVos R, van den Oord JJ, Collen D, Mulligan RCM. Physiological consequences of loss of the plasminogen activator gene function in mice. Nature. 1994;368:419-424.
10. Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann N Y Acad Sci. 1992;667:141-150.
11. Gooding LR. Virus proteins that counteract host immune defenses. Cell. 1992;7:5-7.
12. Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol. 1996;14:101-130.
13. Smith GL. Virus strategies for evasion of the host response to infection. Trends Microbiol. 1994;82:80-88.
14. McFadden G, ed. Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. Austin, Tex: RG Landes Co; 1995.
15. Buller RML, Palumbo GJ. Poxvirus pathogenesis. Microbiol Rev. 1991;55:80-122.
16. McFadden G. Poxviruses: rabbit, hare, squirrel, and swine poxviruses. In: Webster RG, Granoff A, eds. Encyclopedia of Virology. Philadelphia, Pa: WB Saunders Co; 1994:1153-1160.
17. McFadden G, Graham K. Modulation of cytokine networks by poxviruses: the myxoma virus model. Semin Virol. 1994;5:421-429.
18. Upton C, Macen JL, Wishart DS, McFadden G. Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology. 1990;179:618-631.
19. Macen JL, Upton C, Nation N, McFadden G. SERP-1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology. 1993;195:348-363.
20. Turner PC, Musy PY, Moyer RW. Poxvirus serpins. In: McFadden G, ed. Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. Austin, Tex: RG Landes Co; 1995:67-88.
21. IS by a myxoma virus serine proteinase inhibitor. J Biol Chem. 1993;268: 516-521.
22. Nash P, McFadden G. SERP-1. a poxvirus-encoded serpin, is expressed as a glycoprotein that inhibits the inflammatory response to myxoma virus infection. In: Church FC, ed. The Chemistry and Biology of Serpins. New York, NY: Plenum Publishing Corp: 1996.
23. Lee DSC, Griffiths BW. Comparative studies of IODO-BEAD and chloramine-T methods for the radioiodination of human alpha-feto-protein. J Immunol Meth. 1984;74:181-189.
24. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1990;15:475-481.
25. Lucas A, Yue W, Jiang XY, Liu LY, Yan WD, Bauer J, Schneider W, Tulip J, Chagpar A, Dai E, Perk M, Montague P, Garbutt M, Radosavljevic M. Development of an avian model for restenosis. Atherosclerosis. 1996;119:17-41.
26. Gown AM, Tsukada K, Ross R. Human atherosclerosis, II: immunocytochemical analysis of the cellullar composition of human atherosclerotic lesions. Am J Pathol. 1986;125:191-207.
27. Naish SJ, ed. Handbook of Immunochemical Staining Methods. Carpinteria, Calif: Dako Corp; 1989.
28. Hong MK, Bhatti T, Matthews BJ, Stark KS, Seedabarum SC, Foegh ML, Ram well PW, Kent KM. The effect of porous infusion balloon-delivered angiopeptin on myointimal hyperplasia after balloon injury in the rabbit. Circulation. 1993;88:638-648
29. Rasheed Q, Caccione JG, Berry J, Richards F, Bryant L, Strony J, Enger C, Hodgson JM. Local intramural drug delivery using an infusion balloon following angioplasty in normal and atherosclerotic vessels. Cathet Cardiovasc Diagn. 1994;31:240-245.
30. Watanabe Y. Serial inbreeding in rabbits with hereditary hyperlipidemia (WHHC-rabbit). Atherosclerosis. 1980;36:261-268.
31. Lopes-Virella MF, Virella C. Immunological and microbiological factors in the pathogenesis of atherosclerosis, Clin Immunol Immunopathol. 1985;34:377-386.
32. Speir E, Modali R, Huang E-S, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265:391-394.
33. Fabricant CG, Krook L, Gillespie JH. Virus-induced cholesterol crystals. Science. 1973;181:566-567.
34. Hannson GH, Stemm S, Geng YJ, Holm J. Can immunocompetent cells and their cytokines play a role in atherogenesis? Nouv Rev Fr Hematol. 1992;34:543-546.
35. Bradbury AW, Marie JA, Ruckley CV. Role of the leukocyte in the pathogenesis of vascular disease. Br J Surg. 1993;80:1503-1512.
36. Marcus AJ, Hajjar DP. Vascular transcellular signaling. J Lipid Res. 1993;34:2017-2031.
37. Hanke H, Strohschnieder T, Oberhoff M, Betz E, Karsch KR. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res. 1990;67: 651-659.
38. Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irre-spective of the dominant plaque morphology. Circulation. 1994; 89:36-44.
39. Gibbons GH, Dzau VJ. Mechanisms of disease: the emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
40. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J, for the CCAIT group. Effects of monotherapy with an HMG CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation. 1994;89:959-968.
41. Weissberg PL, Grainger DJ, Shanahan CM, Metcalf JC. Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc Res. 1993;27:1191-1198.
42. Forsyth KD, Talbot V, Beckman I. Endothelial serpins: protectors of the vasculature? Clin Exp Immunol. 1994;95:277-282.